Key Takeaways
Multiple law firms are investigating Prestige Consumer Healthcare Inc. (NYSE: PBH) for potential securities law violations after the company’s stock plunged 11.35% following the release of its annual earnings report.
“In Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates,” CEO Ron Lombardi said in the earnings call.
Prestige shares fell $5.88 to close at $45.93 on May 14, 2026, the day after the company disclosed its financial results. The company reported that for fiscal 2026, revenues decreased 4.5% organically compared to the prior year, and the total company adjusted gross margin was 55.6%, approximately flat from 55.8% in the prior year.
The investigations focus on whether Prestige and its executives issued false or misleading statements to investors. This includes a statement from the Q3 earnings call where CEO Ron Lombardi anticipated a 57% adjusted gross margin for Q4, which failed to materialize.
A series of law firms have announced they are investigating the claims on behalf of shareholders who lost money. The firms include Levi & Korsinsky, The Schall Law Firm, Glancy Prongay Wolke & Rotter LLP, the Law Offices of Frank R. Cruz, and Pomerantz LLP. These inquiries could precede the filing of a class-action lawsuit against the company.
The sharp stock decline places Prestige shares at their lowest levels since late 2025, creating a significant legal and financial overhang for the company. The next catalysts for investors will be any formal lawsuits filed or responses from the company regarding the allegations.
This article is for informational purposes only and does not constitute investment advice.
